# Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis

> **NCT04480086** · PHASE1 · TERMINATED · sponsor: **AbbVie** · enrollment: 1 (actual)

## Conditions studied

- Myelofibrosis (MF)

## Interventions

- **DRUG:** Mivebresib
- **DRUG:** Navitoclax
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT04480086
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-17
- **Primary completion:** 2023-07-28
- **Final completion:** 2023-07-28
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Strategic considerations
- **Last updated:** 2023-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04480086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04480086, "Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04480086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*